Publications by authors named "Nadine Abdel Hadi"

Pancreatic ductal adenocarcinoma (PDAC) remains one of the human cancers with the poorest prognosis. Interestingly, we found that mitochondrial respiration in primary human PDAC cells depends mainly on the fatty acid oxidation (FAO) to meet basic energy requirements. Therefore, we treated PDAC cells with perhexiline, a well-recognized FAO inhibitor used in cardiac diseases.

View Article and Find Full Text PDF

Metabolic reprogramming is a feature of cancers for which recent research has been particularly active, providing numerous insights into the mechanisms involved. It occurs across the entire cancer process, from development to resistance to therapies. Established tumors exhibit dependencies for metabolic pathways, constituting vulnerabilities that can be targeted in the clinic.

View Article and Find Full Text PDF

The 4th International meeting Metabolism and Cancer initially programed to take place in Bordeaux (France) was held virtually on May 27-29, 2021. The three-day event was followed by around 600 participants daily from 47 countries around the world. The meeting hosted 21 speakers including selected talks and a keynote lecture from the Nobel Prize winner Sir Peter J.

View Article and Find Full Text PDF

Cell metabolism is reprogrammed in cancer cells to meet their high bioenergetics and biosynthetic demands. This metabolic reprogramming is accompanied by alterations in redox metabolism, characterized by accumulation of reactive oxygen species (ROS). Elevated production of ROS, mostly by mitochondrial respiration, is counteracted by higher production of antioxidant defenses (mainly glutathione and antioxidant enzymes).

View Article and Find Full Text PDF
Article Synopsis
  • Mitochondrial respiration is being explored as a treatment target for pancreatic ductal adenocarcinoma (PDAC), but there is a lack of understanding regarding how it varies among patients.
  • The study finds that PDAC tumors show significant differences in OXPHOS rates, with those having high rates being more responsive to treatments involving phenformin and chemotherapy (gemcitabine).
  • This research suggests a strategy to identify which PDAC patients might benefit from targeting their mitochondrial metabolism in combination with chemotherapy and advocates for clinical trials of phenformin in these specific patient groups.
View Article and Find Full Text PDF